Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: Do the revised breakpoints translate to improved patient outcomes?

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages 965-969

  Tamma, Pranita D ^a   Wu, Harold ^a   Gerber, Jeffrey S ^b   Hsu, Alice J ^a   Tekle, Tsigereda ^a   Carroll, Karen C ^a   Cosgrove, Sara E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Breakpoint; Ceftriaxone; Enterobacteriaceae; Minimum inhibitory concentration; Pediatrics

Indexed keywords

CEFTRIAXONE;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILDHOOD MORTALITY; ENTEROBACTERIACEAE BACTEREMIA; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE SEPSIS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85047687977     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829043b3     Document Type: Article

References (32)

1. Jenkins SG. Rationale Supporting CLSI Changes to Intrepretive Criteria (Breakpoints) for Several Cephalosporins and Aztreonam When Testing Enterobacteriaceae. Washington, DC: American Soceity for Microbiology; 2010:1-4.
2. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect. 2005;2(suppl 6):10-11.
3. Bin C, Hui W, Renyuan Z, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis. 2006;56:351-357.
4. Clinical and Laboratory Standards Institute. CLSI M100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
5. Craig WA, Bhavnani SM, Ambrose PG, et al. Evaluation of clinical outcome among patients with ESBL-producing Enterobcteriaceae treated with cephalosporin mono-therapy ICAAC 2005; Abstract K=1291.
6. Dudley MN, Ambrose PG, Bhavnani SM, et al. Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis. 2013;56:1301-1309.
7. Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol. 2012;33:853-855.
8. Perez F, Bonomo RA. Can we really use B-lactam/B-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum B-lactamase-producing bacteria? Clin Infect Dis. 2012;54:175-177.
9. Queenan AM, Foleno B, Gownley C, et al. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lac tarn ase (ESBL) - producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol. 2004;42:269-275.
10. Custer JW, Rau RE. The Harriet Lane Handbook. 18th ed. Philadelphia: Mosby-Elsevier; 2009.
11. Product Information: ROCEPHIN (R) IV, IM injection, ceftriaxone sodium IV, IMinjection. Nutley, NJ: Roche Laboratories Inc; 2009.
12. Product Information: CLAFORAN (R) IV IM injection, cefotaxime IV IM injection. Bridgewater, NJ: Sanofl-Aventis US LLC; 2007.
13. Garcia L. Clinical Microbiology Procedures Handbook 3rd ed. Washington, DC: American Society for Microbiology; 2010.
14. Tamma PD, Turnbull AE, Milstone AM, et al. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis. 2012;55:799-806.
15. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136:834-844.
16. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10; quiz 11-12.
17. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004;2:289-300.
18. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol. 2000;3:515-521.
19. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
20. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-166.
21. Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther. 2008;6:671-683.
22. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913-920.
23. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162-1171.
24. Rodriguez-Bafio J, Picon E, Navarro MD, et al.; ESBL-REIPI Group. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2012;18:894-900.
25. Rodriguez-Bano J, Navarro MD, Retamar P, et al.; Extended-Spectrum Beta-Lactam as es-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group. β-Lactam/β-lactarn inhibitor combinations for the treatment of bacteremia due to extendedspectrum β-lac tamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167-174.
26. MacGowan A. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect. 2008;14(suppl 1):166-168.
27. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-37.
28. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206-2212.
29. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012;40:297-305.
30. st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-951, table of contents.
31. Siegel JD, Rhinehart E, Jackson M, et al.; Health Care Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10 suppl 2):S65-S164.
32. Siegel JD, Rhinehart E, Jackson M, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10 suppl 2):S165-S193.